As cells expressing EML4-ALK V3 have reduced SAC activity, including in response to the microtubule stabilizing drug paclitaxel, the effect of combining clinically relevant targeted ALK inhibitors with paclitaxel on apoptosis and cell viability was examined in the patient-derived ALK-positive NSCLC cells. Here, EML4 is linked to non-small cell lung carcinoma.